Absolutely. This will be achieved with a 50% death reduction (interim), however we have to bear in mind the POWER of the trial.
Even achieving a good p-value (slightly greater than, say 0.005) the FDA (if given the data from Board) might conclude that the power is not good enough. However, under the circumstances, the information of "drug goodness" is very valuable to us investors, and, by reflection to the SP
One can wait calmly expecting the predictable outcome